Group; mean ± SD* | ||||||
---|---|---|---|---|---|---|
Placebo, n = 34 | Reboxetine, n = 41 | |||||
Characteristic | Val/Val | Val/Met | Met/Met | Val/Val | Val/Met | Met/Met |
COMT genotype, no. (%) | 7 (9.3) | 18 (24.0) | 9 (12.0) | 16 (21.3) | 16 (21.3) | 9 (12.0) |
Smokers, no. (%) | 2 (2.7) | 5 (6.7) | 2 (2.7) | 1 (1.3) | 8 (10.7) | 1 (1.3) |
Age, yr | 21.9 ± 3.9 | 22.1 ± 3.7 | 22.0 ± 3.2 | 22.2 ± 3.7 | 20.8 ± 2.6 | 22.2 ± 2.8 |
Full scale IQ | 109 ± 7 | 113 ± 6 | 112 ± 7 | 110 ± 7 | 111± 7 | 114 ± 6 |
Personality | ||||||
EPQ-E | 17.3 ± 3.5 | 15.1 ± 5.4 | 15.2 ± 6.4 | 15.3 ± 5.2 | 16.0 ± 4.9 | 9.6 ± 4.8 |
EPQ-N | 12.4 ± 4.4 | 10.6 ± 5.3 | 12.0 ± 5.5 | 12.8 ± 3.7 | 13.3 ± 4.7 | 13.9 ± 6.3 |
COMT = catechol-O-methyltransferase; EPQ-E = Eysenck Personality Questionnaire–Extraversion; EPQ-N = Eysenck Personality Questionnaire–Neuroticism; SD = standard deviation.
↵* Unless otherwise indicated.